HBM HLDGS LTD DL-000025 Market Cap ($1.14 Billion)
Market Cap & Net Worth: HBM HLDGS LTD DL-000025 (6XY)
HBM HLDGS LTD DL-000025 market cap. HBM HLDGS LTD DL-000025 (F:6XY) has a market capitalization of $1.14 Billion (€972.87 Million) as of November 8, 2026. Listed on the F stock exchange, this Germany-based company holds position #8061 globally and #1093 in its home market, demonstrating a 2.65% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HBM HLDGS LTD DL-000025's stock price €1.16 by its total outstanding shares 838684362 (838.68 Million). Also see HBM HLDGS LTD DL-000025 (6XY) cash conversion ratio for how efficiently the company converts equity into cash flow.
HBM HLDGS LTD DL-000025 Market Cap History (2021–2026)
HBM HLDGS LTD DL-000025 market cap history from 2021 to 2026. Data shows growth from $813.82 Million to $1.14 Billion (3.32% CAGR). Check HBM HLDGS LTD DL-000025 stock quote for real-time trading data and today's change.
HBM HLDGS LTD DL-000025 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HBM HLDGS LTD DL-000025's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of HBM HLDGS LTD DL-000025 to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
7.94x
HBM HLDGS LTD DL-000025's market cap is 7.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.74x
HBM HLDGS LTD DL-000025's market cap is 13.74 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $813.82 Million | $4.31 Million | -$137.78 Million | 188.91x | N/A |
| 2022 | $300.04 Million | $40.66 Million | -$137.22 Million | 7.38x | N/A |
| 2023 | $148.06 Million | $89.50 Million | $22.80 Million | 1.65x | 6.49x |
| 2024 | $189.24 Million | $38.10 Million | $2.78 Million | 4.97x | 68.12x |
| 2025 | $1.26 Billion | $157.97 Million | $91.33 Million | 7.94x | 13.74x |
Competitor Companies of 6XY by Market Capitalization
Companies near HBM HLDGS LTD DL-000025 in the global market cap rankings as of November 8, 2026. Also see 6XY asset base for a full breakdown of the balance sheet.
Key companies related to HBM HLDGS LTD DL-000025 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of HBM HLDGS LTD DL-000025 (2021–2026)
Market capitalization of HBM HLDGS LTD DL-000025 from 2021 to today. Between 2021 and today, HBM HLDGS LTD DL-000025's market cap moved from $813.82 Million to $ 1.14 Billion, with a yearly change of 3.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.14 Billion | -9.38% |
| 2025 | €1.26 Billion | +563.21% |
| 2024 | €189.24 Million | +27.81% |
| 2023 | €148.06 Million | -50.65% |
| 2022 | €300.04 Million | -63.13% |
| 2021 | €813.82 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of HBM HLDGS LTD DL-000025 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.14 Billion USD |
| MoneyControl | $1.14 Billion USD |
| MarketWatch | $1.14 Billion USD |
| marketcap.company | $1.14 Billion USD |
| Reuters | $1.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About HBM HLDGS LTD DL-000025
HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company i… Read more